Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 11;9(5):1427.
doi: 10.3390/jcm9051427.

MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

Maria Grazia Rodriquenz  1 , Giandomenico Roviello  2 , Alberto D'Angelo  3 , Daniele Lavacchi  4 , Franco Roviello  5 , Karol Polom  6
Affiliations
Review

MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

Maria Grazia Rodriquenz et al. J Clin Med. .

Abstract

Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes- Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer's subgroups and their relationship with novel immunotherapy.

Keywords: EBV; MSI; immunotherapy; molecular subtypes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

Figures

Figure 1
Figure 1
Molecular interaction in microsatellite-unstable/instability (MSI) end. Epstein-Barr virus (EBV) gastric cancer (GC).
See this image and copyright information in PMC

References

    1. Chia N.-Y., Tan P. Molecular classification of gastric cancer. Ann. Oncol. 2016;27:763–769. doi: 10.1093/annonc/mdw040. - DOI - PubMed
    1. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X. - DOI - PubMed
    1. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. doi: 10.1038/nature13480. - DOI - PMC - PubMed
    1. Cristescu R., Lee J., Nebozhyn M., Kim K.M., Ting J.C., Wong S.S., Liu J., Yue Y.G., Wang J., Yu K., et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 2015;21:449–456. doi: 10.1038/nm.3850. - DOI - PubMed
    1. Kankeu Fonkoua L., Yee N.S. Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. Biomedicines. 2018;6:32. doi: 10.3390/biomedicines6010032. - DOI - PMC - PubMed

LinkOut - more resources